License and Development Agreements - Endo License and Development Agreement - Additional Information (Detail) $ in Thousands		1 Months Ended				12 Months Ended
	Oct. 26, 2015 USD ($)	Nov. 30, 2015 USD ($)	Oct. 31, 2015 USD ($)	Feb. 28, 2015 USD ($)	May 31, 2012 USD ($)	Dec. 31, 2016 USD ($) Clinical_Trials	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2014 USD ($)	Jan. 31, 2014 USD ($)	Jan. 31, 2012 USD ($)
Revenue Recognition, Milestone Method [Line Items]
Non-refundable payment received											$ 30,000
Potential milestone payments on intellectual property rights					$ 15,000
Potential payments upon filing and acceptance				$ 10,000
Potential milestone payment receivable upon regulatory approval	$ 50,000		$ 50,000
Milestone payment upon regulatory approval deferred for future revenue recognition		$ 20,000
Patent extension starting period						2020
Patent extension ending period						2027
Royalty payment description						$50 million upon regulatory approval, earned in October 2015 and received in November 2015. Of the $50 million received in November 2015, $20 million related to a patent extension and was recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027. However, due to the Company and Endo entering into a Termination Agreement on December 7, 2016 which terminated the BELBUCA® license to Endo effective January 6, 2017, the deferred $20 million will be recognized as revenue in January 2017. (See note 15).
Recognized up-front payment allocated to the license						$ 15,600
Recognized up-front payment to clinical trial material and development services						14,400
Contract revenues						$ 2,500	$ 41,759	$ 22,749
Total rate of reimbursable contractor costs borne						50.00%
Deferred revenue from research and development activities						$ 1,134	909	12,712
Deferred revenue recognized during the period						6,000		6,000
Milestone payment receivable remaining revenue							30,000
Clinical Trials Full Enrollment [Member]
Revenue Recognition, Milestone Method [Line Items]
Potential milestone payment received, clinical development						$ 20,000
Number of clinical trials | Clinical_Trials						2
Clinical Trials One [Member]
Revenue Recognition, Milestone Method [Line Items]
Potential milestone payment received, clinical development										$ 10,000
Clinical Trials Two [Member]
Revenue Recognition, Milestone Method [Line Items]
Potential milestone payment received, clinical development									$ 10,000
Endo Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Contract revenues						$ 0	400	2,500
Total rate of reimbursable contractor costs borne						50.00%
Reimbursement rate of costs by Endo to the company as per agreement						100.00%
Percentage of credit against potential future milestones						50.00%
Deferred revenue from research and development activities						$ 0	$ 900	$ 12,700
Endo Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Deferred revenue refund payment						$ 20,000
Termination agreement date						Dec. 07, 2016
License termination effective date						Jan. 06, 2017